

Syncona portfolio firm Freeline cuts workforce and narrows focus


Syncona invests GBP19 million in Quell Therapeutics via funding round


EXECUTIVE CHANGES: All change at Aura Energy amid ASX spin-out plan


IN BRIEF: Syncona net assets drop as Life Science portfolio takes hit


(Sharecast News) - Healthcare investor Syncona reported net assets of £1.15bn at the end of its first half on Thursday, or 171.7p per share, down...


Syncona's Freeline loss widens but progresses on Fabry's disease drug


(Sharecast News) - Healthcare company Syncona announced new data from its portfolio company Freeline Therapeutics' ongoing phase 1 and 2 'MARVEL-1' do...


TRADING UPDATES: Sealand's China progress; Altus finds gold